lansoprazole has been researched along with lansoprazole sulfone in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldstein, JA; Parkinson, A; Pearce, RE; Rodrigues, AD | 1 |
| Ishizaki, T; Kim, HK; Kwon, JT; Sohn, DR | 1 |
| Arimori, K; Fujii, J; Masa, K; Miyamoto, S; Nakano, M; Nakayama, T | 1 |
| Arimori, K; Fujii, J; Hamada, A; Masa, K; Nakano, M | 1 |
| Arimori, K; Hamada, A; Katsuki, H; Nakamura, C; Nakano, M | 2 |
| Echizen, H; Nachi, S; Ohnishi, A; Ushiama, H | 1 |
| Ali, E; Bandyopadhyay, U; Banerjee, RK; Biswas, K; Chattopadhyay, I; Varadaraj, A | 1 |
| Miura, M; Suzuki, T; Tada, H | 1 |
| Miura, M; Sugawara, K; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 2 |
| Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Munakata, A; Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Kagaya, H; Miura, M; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Gao, X; Hang, T; Song, M; Wen, A | 1 |
| Hayashi, M; Kinoshita, Y; Kobayashi, S; Kumai, T; Matsumoto, N; Suzuki, S; Takeba, Y; Watanabe, M; Yanagida, Y | 1 |
| Chen, WL; Chu, NN; Li, XN; Xu, HR | 1 |
| Liu, H; Wang, G; Wang, X; Yang, M; Zhang, D | 1 |
| Liu, H; Liu, M; Wang, X; Xiao, X; Yang, M; Zhang, D; Zhang, Y | 1 |
| Han, J; Liu, H; Liu, M; Wang, X; Yang, M; Zhang, D; Zhang, Y | 1 |
10 trial(s) available for lansoprazole and lansoprazole sulfone
| Article | Year |
|---|---|
Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; Korea; Lansoprazole; Male; Mephenytoin; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors | 1997 |
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrocortisone; Lansoprazole; Liver Function Tests; Male; Middle Aged; Omeprazole; Oxidoreductases, N-Demethylating; Penicillins; Protein Synthesis Inhibitors | 2002 |
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Dexlansoprazole; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Time Factors | 2004 |
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Synergism; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Selective Serotonin Reuptake Inhibitors | 2004 |
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Genotype; Heterozygote; Homozygote; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Protein Synthesis Inhibitors; Proton Pump Inhibitors | 2005 |
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2005 |
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Beverages; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Female; Humans; Intestines; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Stereoisomerism | 2006 |
The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Enzyme Activation; Genetic Carrier Screening; Homozygote; Humans; Lansoprazole; Male; Proton Pump Inhibitors; Young Adult | 2010 |
Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; China; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Humans; Injections, Intravenous; Lansoprazole; Male; Polymorphism, Genetic; Young Adult | 2012 |
Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Humans; Infusions, Intravenous; Lansoprazole; Male; Proton Pump Inhibitors; Sex Characteristics; Young Adult | 2013 |
11 other study(ies) available for lansoprazole and lansoprazole sulfone
| Article | Year |
|---|---|
Identification of the human P450 enzymes involved in lansoprazole metabolism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; Lansoprazole; Microsomes, Liver; Omeprazole; Rats; Recombinant Proteins | 1996 |
Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dogs; Drug Interactions; Hydroxylation; In Vitro Techniques; Lansoprazole; Male; Microsomes, Liver; Omeprazole | 1999 |
Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Area Under Curve; Biotransformation; Cytochrome P-450 Enzyme System; Dogs; Drug Interactions; Enzyme Inhibitors; Half-Life; In Vitro Techniques; Isoenzymes; Lansoprazole; Male; Microsomes, Liver; Omeprazole; Protein Binding; Proton Pump Inhibitors; Stereoisomerism | 2001 |
High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Calibration; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stereoisomerism | 2001 |
Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Lansoprazole; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Protein Isoforms; Proton Pump Inhibitors; Stereoisomerism | 2001 |
A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antioxidants; Apoptosis; DNA Damage; Free Radical Scavengers; Hydroxyl Radical; Lansoprazole; Omeprazole; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Stomach Ulcer | 2003 |
Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Humans; Kidney Transplantation; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 2004 |
Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chromatography, High Pressure Liquid; Female; Humans; Lansoprazole; Male; Omeprazole; Reproducibility of Results; Sensitivity and Specificity; Sulfones | 2005 |
Simultaneous determination of lansoprazole and its metabolites 5'-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Area Under Curve; Chromatography, Liquid; Drug Stability; Freezing; Guidelines as Topic; Half-Life; Humans; Indapamide; Lansoprazole; Metabolic Clearance Rate; Methanol; Molecular Structure; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; United States; United States Food and Drug Administration; Water | 2008 |
Potential of lansoprazole as a novel probe for cytochrome P450 3A activity by measuring lansoprazole sulfone in human liver microsomes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antibodies, Monoclonal; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; In Vitro Techniques; Lansoprazole; Metabolic Detoxication, Phase I; Microsomes, Liver; Molecular Probes; Steroid Hydroxylases; Sulfones | 2009 |
Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; China; Cytochrome P-450 CYP2C19; Humans; Lansoprazole; Male; Polymorphism, Single Nucleotide; Young Adult | 2011 |